Paclitaxel Patent Expiration

Paclitaxel is used for treating tumors, breast cancer, lung cancer, and pancreatic cancer. It was first introduced by Hq Specialty Pharma Corp in its drug Taxol on Dec 29, 1992. Other drugs containing Paclitaxel are Paclitaxel, Abraxane. 18 different companies have introduced drugs containing Paclitaxel.


Paclitaxel Patents

Given below is the list of patents protecting Paclitaxel, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Abraxane US5439686 Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor Feb 22, 2013

(Expired)

Bristol-myers
Abraxane US5498421 Composition useful for in vivo delivery of biologics and methods employing same Mar 12, 2013

(Expired)

Bristol-myers
Abraxane US6096331 Methods and compositions useful for administration of chemotherapeutic agents Feb 22, 2013

(Expired)

Bristol-myers
Abraxane US6506405 Methods and formulations of cremophor-free taxanes Feb 22, 2013

(Expired)

Bristol-myers
Abraxane US6537579 Compositions and methods for administration of pharmacologically active compounds Feb 22, 2013

(Expired)

Bristol-myers
Abraxane US6749868 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof Feb 22, 2013

(Expired)

Bristol-myers
Abraxane US6753006 Paclitaxel-containing formulations Feb 22, 2013

(Expired)

Bristol-myers
Abraxane US7758891 Combinations and modes of administration of therapeutic agents and combination therapy Feb 21, 2026 Bristol-myers
Abraxane US7758891

(Pediatric)

Combinations and modes of administration of therapeutic agents and combination therapy Aug 21, 2026 Bristol-myers
Abraxane US7820788 Compositions and methods of delivery of pharmacological agents Oct 27, 2024 Bristol-myers
Abraxane US7820788

(Pediatric)

Compositions and methods of delivery of pharmacological agents Apr 27, 2025 Bristol-myers
Abraxane US7923536 Compositions and methods of delivery of pharmacological agents Dec 09, 2023

(Expired)

Bristol-myers
Abraxane US7923536

(Pediatric)

Compositions and methods of delivery of pharmacological agents Jun 09, 2024

(Expired)

Bristol-myers
Abraxane US8034375 Combinations and modes of administration of therapeutic agents and combination therapy Aug 13, 2026 Bristol-myers
Abraxane US8034375

(Pediatric)

Combinations and modes of administration of therapeutic agents and combination therapy Feb 13, 2027 Bristol-myers
Abraxane US8138229 Compositions and methods of delivery of pharmacological agents Dec 09, 2023

(Expired)

Bristol-myers
Abraxane US8138229

(Pediatric)

Compositions and methods of delivery of pharmacological agents Jun 09, 2024

(Expired)

Bristol-myers
Abraxane US8268348 Combinations and modes of administration of therapeutic agents and combination therapy Feb 21, 2026 Bristol-myers
Abraxane US8268348

(Pediatric)

Combinations and modes of administration of therapeutic agents and combination therapy Aug 21, 2026 Bristol-myers
Abraxane US8314156 Compositions and methods of delivery of pharmacological agents Dec 09, 2023

(Expired)

Bristol-myers
Abraxane US8314156

(Pediatric)

Compositions and methods of delivery of pharmacological agents Jun 09, 2024

(Expired)

Bristol-myers
Abraxane US8853260 Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof Oct 10, 2020

(Expired)

Bristol-myers
Abraxane US8853260

(Pediatric)

Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof Apr 10, 2021

(Expired)

Bristol-myers
Abraxane US9101543 Combinations and modes of administration of therapeutic agents and combination therapy Feb 21, 2026 Bristol-myers
Abraxane US9101543

(Pediatric)

Combinations and modes of administration of therapeutic agents and combination therapy Aug 21, 2026 Bristol-myers
Abraxane US9393318 Methods of treating cancer Mar 04, 2032 Bristol-myers
Abraxane US9393318

(Pediatric)

Methods of treating cancer Sep 04, 2032 Bristol-myers
Abraxane US9511046 Methods of treating pancreatic cancer Jan 12, 2034 Bristol-myers
Abraxane US9511046

(Pediatric)

Methods of treating pancreatic cancer Jul 12, 2034 Bristol-myers
Abraxane US9597409 Methods of treating cancer Mar 04, 2032 Bristol-myers
Abraxane US9597409

(Pediatric)

Methods of treating cancer Sep 04, 2032 Bristol-myers
Abraxane USRE41884 Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions Aug 14, 2016

(Expired)

Bristol-myers


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Paclitaxel Generics

Several generic applications have been filed for Paclitaxel. The first generic version for Paclitaxel was by Teva Pharmaceuticals Usa and was approved on Jan 25, 2002. And the latest generic version is by Alembic Pharmaceuticals Ltd and was approved on Oct 20, 2022.

Given below is the list of companies who have filed for Paclitaxel generic.


1. PLIVA LACHEMA

Pliva Lachema As has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Pliva Lachema.

Strength Dosage Form Availability Application Pathway TE code Launch Date
6MG/ML injectable Discontinued INJECTION N/A Mar 12, 2008


2. GLAND PHARMA LTD

Gland Pharma Ltd has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Gland Pharma Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
6MG/ML injectable Prescription INJECTION AP Aug 23, 2016


3. ALEMBIC

Alembic Pharmaceuticals Ltd has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Alembic.

Strength Dosage Form Availability Application Pathway TE code Launch Date
6MG/ML injectable Prescription INJECTION AP Oct 20, 2022


4. TEVA PHARMS USA

Teva Pharmaceuticals Usa has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.

Strength Dosage Form Availability Application Pathway TE code Launch Date
6MG/ML injectable Discontinued INJECTION N/A Jan 25, 2002


5. HIKMA

Hikma Pharmaceuticals Usa Inc has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Hikma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
6MG/ML injectable Prescription INJECTION AP Jan 28, 2002


6. DASH PHARMS

Dash Pharmaceuticals Llc has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Dash Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
6MG/ML injectable Discontinued INJECTION N/A Sep 29, 2011


7. ACTAVIS TOTOWA

Actavis Totowa Llc has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Actavis Totowa.

Strength Dosage Form Availability Application Pathway TE code Launch Date
6MG/ML injectable Prescription INJECTION AP Dec 9, 2009


8. MYLAN

Mylan Pharmaceuticals Inc has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Mylan.

Strength Dosage Form Availability Application Pathway TE code Launch Date
6MG/ML injectable Discontinued INJECTION N/A Jan 25, 2002


9. ACCORD HLTHCARE

Accord Healthcare Inc has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.

Strength Dosage Form Availability Application Pathway TE code Launch Date
6MG/ML injectable Prescription INJECTION AP Aug 17, 2018


10. FRESENIUS KABI USA

Fresenius Kabi Usa Llc has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Fresenius Kabi Usa.

Strength Dosage Form Availability Application Pathway TE code Launch Date
6MG/ML injectable Prescription INJECTION AP Nov 27, 2006


11. SANDOZ

Sandoz Inc has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Sandoz.

Strength Dosage Form Availability Application Pathway TE code Launch Date
6MG/ML injectable Discontinued INJECTION N/A Dec 26, 2007


12. TEVA PHARMS

Teva Pharmaceuticals Usa has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Teva Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
6MG/ML injectable Prescription INJECTION AP Jan 25, 2002


13. MSN

Msn Laboratories Private Ltd has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Msn.

Strength Dosage Form Availability Application Pathway TE code Launch Date
6MG/ML injectable Prescription INJECTION AP Aug 24, 2020


14. HOSPIRA

Hospira Inc has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Hospira.

Strength Dosage Form Availability Application Pathway TE code Launch Date
6MG/ML injectable Discontinued INJECTION N/A Aug 1, 2002